Trends in Allogeneic Transplantation for Favorable Risk Acute Myeloid Leukemia in First Remission: a Longitudinal Study of >15 Years from the ALWP of the EBMT

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2024 Aug 20

PMID 39164484

Authors

Arnon Nagler

Myriam Labopin

Urpu Salmenniemi

Depei Wu

Didier Blaise

Alessandro Rambaldi

Peter Remenyi

Edouard Forcade

Gerard Socie

Patrice Chevallier

Peter Von Dem Borne

David Burns

Christoph Schmid

Johan Maertens

Nicolaus Kroger

Gesine Bug

Mahmoud Aljurf

Jan Vydra

Kazimierz Halaburda

Fabio Ciceri

Mohamad Mohty

Affiliations

Soon will be listed here.

Abstract

We assessed outcomes of allogeneic transplantation (HSCT) in favorable risk AML in CR1 over 3 time periods. 1850 patients were included, 2005 to 2009- 222, 2010 to 2014 -392, and 2015 to 2021-1236; 526 with t (8:21), 625 with inv (16), and 699 with NPM1FLT3. Patients transplanted in 2015-2021 were older (p < 0.0001) with more patients ≥60 years of age (p < 0.0001). The most frequent diagnosis in 2015-2021 was NPM1FLT3 vs. t (8:21) in the 2 earlier periods, (p < 0001). Haploidentical transplants (Haplo) increased from 5.9% to 14.5% (p < 0.0001). Graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) was more frequent in 2015-2021 vs. the other 2 periods (p < 0.0001). On multivariate analysis, incidence of total chronic GVHD was reduced in HSCTs performed ≥2015 vs. those performed in 2005-2009, hazard ratio (HR) = 0.74 (95% CI 0.56-0.99, p = 0.046) and GVHD-free, relapse-free survival (GRFS) improved for patients transplanted from 2010-2014 vs. those transplanted in 2005-2009, HR = 0.74 (95% CI 0.56-0.98, p = 0.037). Other HSCT outcomes did not differ with no improvement ≥2015. LFS, OS, and GRFS were inferior in patients with t (8:21) with HR = 1.32 (95% CI 1.03-1.68, p = 0.026), HR = 1.38 (95% CI 1.04-1.83, p = 0.027) and HR = 01.25 (95% CI 1.02-1.53, p = 0.035), respectively. In conclusion, this retrospective analysis of HSCT in patients with favorable risk AML, transplanted over 16 years showed an increased number of transplants in patients ≥60 years, from Haplo donors with PTCy. Most importantly, 3-year GRFS improved ≥2010 and total chronic GVHD reduced ≥2015, with no significant change in other HSCT outcomes.

References

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

Arber D, Orazi A, Hasserjian R, Borowitz M, Calvo K, Kvasnicka H . International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228. PMC: 9479031. DOI: 10.1182/blood.2022015850. View

Shimony S, Stahl M, Stone R . Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023; 98(3):502-526. DOI: 10.1002/ajh.26822. View

Shouval R, Fein J, Labopin M, Cho C, Bazarbachi A, Baron F . Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021; 8(3):e205-e215. PMC: 9190021. DOI: 10.1016/S2352-3026(20)30394-X. View

Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F . Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data.... J Clin Oncol. 2015; 33(28):3144-51. DOI: 10.1200/JCO.2014.59.1339. View

Borthakur G, Kantarjian H . Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021; 11(6):114. PMC: 8209225. DOI: 10.1038/s41408-021-00503-6. View

Boddu P, Kantarjian H, Borthakur G, Kadia T, Daver N, Pierce S . Co-occurrence of -TKD and mutations defines a highly favorable prognostic AML group. Blood Adv. 2018; 1(19):1546-1550. PMC: 5728474. DOI: 10.1182/bloodadvances.2017009019. View

Schlenk R, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G . Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004; 22(18):3741-50. DOI: 10.1200/JCO.2004.03.012. View

Mosna F, Papayannidis C, Martinelli G, Di Bona E, Bonalumi A, Tecchio C . Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. Am J Hematol. 2015; 90(6):515-23. DOI: 10.1002/ajh.24000. View

10.

Falini B, Brunetti L, Martelli M . How I diagnose and treat NPM1-mutated AML. Blood. 2020; 137(5):589-599. DOI: 10.1182/blood.2020008211. View

11.

Cornelissen J, Gratwohl A, Schlenk R, Sierra J, Bornhauser M, Juliusson G . The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012; 9(10):579-90. DOI: 10.1038/nrclinonc.2012.150. View

12.

Halaburda K, Labopin M, Mailhol A, Socie G, Craddock C, Aljurf M . Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2019; 105(6):1723-1730. PMC: 7271580. DOI: 10.3324/haematol.2019.222810. View

13.

Loke J, Buka R, Craddock C . Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?. Front Immunol. 2021; 12:659595. PMC: 8126705. DOI: 10.3389/fimmu.2021.659595. View

14.

Bazarbachi A, Schmid C, Labopin M, Beelen D, Blau I, Potter V . Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clin Cancer Res. 2020; 26(24):6475-6482. DOI: 10.1158/1078-0432.CCR-20-3134. View

15.

Nagler A, Ngoya M, Galimard J, Labopin M, Bornhauser M, Stelljes M . Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT Analysis. Clin Cancer Res. 2022; 28(19):4258-4266. DOI: 10.1158/1078-0432.CCR-22-0809. View

16.

Bazarbachi A, Labopin M, Gedde-Dahl T, Remenyi P, Forcade E, Kroger N . Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party. Clin Cancer Res. 2023; 29(21):4441-4448. DOI: 10.1158/1078-0432.CCR-23-0954. View

17.

Shouval R, Fein J, Labopin M, Kroger N, Duarte R, Bader P . Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019; 6(11):e573-e584. DOI: 10.1016/S2352-3026(19)30158-9. View

18.

Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S . How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020; 4(24):6283-6290. PMC: 7756984. DOI: 10.1182/bloodadvances.2020003418. View

19.

Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji R . Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. J Intern Med. 2018; 285(4):407-418. DOI: 10.1111/joim.12854. View

20.

McDonald G, Sandmaier B, Mielcarek M, Sorror M, Pergam S, Cheng G . Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. Ann Intern Med. 2020; 172(4):229-239. PMC: 7847247. DOI: 10.7326/M19-2936. View